ライフサイエンスコーパス: residual tumor

1 n time groups overall or among patients with residual tumor.

2 hemotherapy, and 93 were observed with gross residual tumor.

3 of delaying resection, even in patients with residual tumor.

4 Eight patients had no evidence of residual tumor.

5 subsequent laparotomy revealed small-volume residual tumor.

6 ment session; this finding was indicative of residual tumor.

7 lay a role in the elimination of microscopic residual tumor.

8 y tumors demonstrating small areas of viable residual tumor.

9 wed no (T0) or only non-muscle-invasive (T1) residual tumor.

10 section cavity boundary was not specific for residual tumor.

11 respectively) (P < .001) in the depiction of residual tumor.

12 dissections, four of which were positive for residual tumor.

13 instances, this was associated with obvious residual tumor.

14 rfere with the detection of small amounts of residual tumor.

15 y (100% in this cohort) for detecting viable residual tumor.

16 Thirteen (23%) of 56 women had no residual tumor.

17 eeks after treatment revealed no evidence of residual tumor.

18 ironment that enhances growth of microscopic residual tumor.

19 ed early (within 4 months) repeat of NSS for residual tumor.

20 ative for residual tumor versus positive for residual tumor.

21 herapy followed by surgical resection of the residual tumor.

22 xamination of the resection cavity walls for residual tumor.

23 pathologic complete response, whereas 14 had residual tumor.

24 uld not be confirmed by iMRI, which detected residual tumor.

25 tients had undergone primary surgery with no residual tumor.

26 Postop plasma may stimulate the growth of residual tumor.

27 ucleated at 21 weeks of age and examined for residual tumor.

28 esent a novel approach toward eradication of residual tumors.

29 ventional histological analysis in detecting residual tumors.

30 After BCG, 66 specimens were TO and 32 had residual tumors.

31 a may be useful agent in retarding growth of residual tumors.

32 hoice between eradication versus regrowth of residual tumors.

33 duce the negative effect of tissue repair on residual tumors.

34 ucibility after subtraction of the estimated residual tumor activity from the first (18)F-FLT injecti

35 For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combinat

36 rease in CD4+ and CD8+ T-cell numbers at the residual tumor after androgen ablation.

37 The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin

38 igh positive predictive value for predicting residual tumor after excisional biopsy.

39 erapy (seven with pathologic IBC, three with residual tumor after mastectomy).

40 For detection of residual tumor after polypectomy, endorectal US had a se

41 nical course, and in 2 patients PET detected residual tumor after presumably complete tumor resection

42 otherapy (HIPEC) is to eradicate microscopic residual tumor after radical surgical tumor excision in

43 y effects, and 11 scans for the detection of residual tumor after resection were obtained.

44 /or radiotherapy, and only two of the 10 had residual tumor after surgery.

45 , T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery.

46 The residual tumor after treatment in tumors that were initi

47 like cells (CSC) are selectively enriched in residual tumors after anticancer therapies, which may ac

48 sistent gene expression pattern was found in residual tumors after docetaxel treatment.

49 Children with no residual tumors after induction therapy and no metastati

50 Residual tumor AGT activity, present 18 h after BG doses

51 fluorescent molecules, we are able to detect residual tumor and metastases as small as 200 microm, wh

52 mary central nervous system lymphoma without residual tumor and pituitary tumors were reported recent

53 tment efficacy on the basis of the extent of residual tumor and regressive changes within tumor tissu

54 ed in patients without a large postoperative residual tumor and without RT treatment delays.

55 would elicit an immune response directed at residual tumor and would reduce the incidence of recurre

56 splatin-resistant CD133(+)/CXCR4(+) cells in residual tumors and their metastatization.

57 stoma multiforme), as well as age, amount of residual tumor, and tumor location.

58 f nonapoptotic cells by approximately 70% in residual tumors, and enhanced the fraction of apoptotic

59 Irradiation was used only for residual tumor at consolidation or for progressive/recur

60 a T2 tumor but who was found to have a small residual tumor at mammography and US performed at the ti

61 Patients with less than 1 cm(3) residual tumor at mastectomy received an additional five

62 ely infiltrative properties of GBM result in residual tumor at neurosurgical resection margins, repre

63 nts for at least 1 year, with no evidence of residual tumor at serial CA-125 analysis or subsequent l

64 In nonresponding patients, the risk of residual tumor at surgery was 100% (vs. 45% in responder

65 therapy (24 Gy) in patients with significant residual tumor at surgery.

66 resection EGD, but seven of the 17 (41%) had residual tumor at surgery.

67 crease in (18)F-FDG uptake at 2 cycles means residual tumor at the end of NAC and a high risk of earl

68 re, when post-operative pathology identifies residual tumor at the surgical margins, re-excision surg

69 Among 18 patients with residual tumor at the time of vaccination, 4 (22%) had t

70 or-resection procedures in order to identify residual tumors at the margins and to guide their comple

71 For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predi

72 small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless,

73 che" that promotes the survival of a minimal residual tumor burden and serves as a reservoir for even

74 Residual tumor burden following treatment of ALK or ROS1

75 st cancer therapy response, as determined by residual tumor burden on pathology, were evaluated.

76 Eyes were analyzed at 16 weeks of age for residual tumor burden, which was measured by gauging the

77 xenografts correlated inversely with visible residual tumor burden.

78 of residual tumor, versus > or = 1.5 cm2 of residual tumor by scan, were significantly different (P

79 des I to IV based on the percentage of vital residual tumor cells (VRTCs).

80 are important for clearing small numbers of residual tumor cells after chemotherapy-mediated cytored

81 ight represent a novel approach to eliminate residual tumor cells after surgery and increase the effe

82 infection enhances the invasive capacity of residual tumor cells after surgery, thus facilitating th

83 ell transplantations (ASCTs) might eradicate residual tumor cells and decrease relapse rates.

84 geon to delineate tumor margins, to identify residual tumor cells and micrometastases, and to determi

85 h signaling in tumor recurrence from dormant residual tumor cells and provide evidence that dormancy

86 can lead to tumor progression suggests that residual tumor cells are, in fact, quiescent and, theref

87 tem cells in the resection cavity eradicated residual tumor cells by inducing caspase-mediated apopto

88 or these diseases but is often undermined by residual tumor cells contaminating the graft.

89 n (interquartile range [IQR]) percentages of residual tumor cells for optimal morphologic response wa

90 nation was thus associated with clearance of residual tumor cells from blood and long-term disease-fr

91 The MARI node contained residual tumor cells in 65 of these 95 patients.

92 ed on the extent of regressional changes and residual tumor cells in the resection specimen.

93 ed on the extent of regressional changes and residual tumor cells in the resection specimen.

94 nical remission, implying that at least some residual tumor cells pass through a dormant phase prior

95 tion and p-STAT3[Y705] activation within the residual tumor cells surviving the initial antitumor res

96 To define early molecular changes within residual tumor cells that persist after treatment, we an

97 ing remains activated in a subset of dormant residual tumor cells that persist following HER2/neu dow

98 cell lung cancer (NSCLC) to characterize the residual tumor cells that survive chemotherapy treatment

99 breast cancer, and Par-4 is downregulated in residual tumor cells that survive neoadjuvant chemothera

100 urrent tumors that arise from a reservoir of residual tumor cells that survive therapy.

101 ft-versus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms.

102 With RECIST, the median (IQR) percentages of residual tumor cells were for partial response 30% (10%-

103 (>/=TRG2) and in 63 of these patients (89%), residual tumor cells were seen in the mucosa and/or subm

104 gen itself, either injected or released from residual tumor cells, would boost the antibody response.

105 effects that go beyond the direct killing of residual tumor cells.

106 sue that complicates the complete removal of residual tumor cells.

107 Analysis of sections of residual tumor confirmed replication of MV within the tu

108 In addition, residual tumors contained less CD133+ cancer cells follo

109 ations were categorized according to whether residual tumor could be definitely identified or exclude

110 T (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a t

111 lete response, and nine had </= 0.2 cm(3) of residual tumor (defined as a near-complete response), wi

112 at we analyzed, all but 3 had no evidence of residual tumor (defined as negative surgical margins) fo

113 confirmed conjunctival SCC in all cases with residual tumor demonstrating scleral invasion (n = 15) a

114 ototype handheld imaging device can identify residual tumor during intraoperative molecular imaging.

115 patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary

116 g a role of adaptive immunity in controlling residual tumor foci.

117 the role of salvage CR in patients who have residual tumor following CR, a phase III randomized tria

118 pathologic response by determining extent of residual tumor following CRT (P0, 0% residual; P1, 1%-50

119 who had no surgical or clinical evidence of residual tumor for 1 year.

120 Twenty-nine specimens contained sufficient residual tumor for inclusion in a tissue microarray.

121 uced at comparison of pre- and posttreatment residual tumor for women with pPR (n = 4) (P = .033).

122 Notably, residual tumors from an unselected group of BC patients

123 complete tumor necrosis is uncommon, and the residual tumor generally rapidly recurs.

124 fer with hematopoietic stem cells suppresses residual tumor growth (graft-versus-tumor [GVT]) in canc

125 itate liver regeneration) may play a role in residual tumor growth.

126 0 tumors, > or = 3 years with < or = 1.5 cm2 residual tumor, had a 78%+/-6% 5-year PFS rate.

127 supine) and may help clinicians evaluate for residual tumor immediately after BCS.

128 (prone) to surgery (supine) and to evaluate residual tumor immediately after breast-conserving surge

129 m-enhanced MR imaging correctly demonstrated residual tumor in 20 of 23 patients.

130 Axillary lymph node examination revealed residual tumor in 33% of patients who received 8 x CVAP

131 ive mortality rate was 4.2% with evidence of residual tumor in 34.6% of specimens.

132 , 89%) and CA-125 values, which demonstrated residual tumor in 44 patients (sensitivity, 65%; specifi

133 compared with laparotomy, which demonstrated residual tumor in 60 patients (sensitivity, 88%; specifi

134 Gadolinium-enhanced MR imaging depicted residual tumor in 61 patients (sensitivity, 90%; specifi

135 ablation by decreasing the tumor volume and residual tumor in an experimental carcinoma model.

136 cystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineu

137 should be followed by surgical resection of residual tumor in nonseminomatous GCT.

138 1311 in the ablation of a thyroid remnant or residual tumor in patients with differentiated thyroid c

139 Both surgical specimens revealed residual tumor in regions that were not in direct commun

140 CAIX-expressing tumors and the assessment of residual tumor in resection margins or metastatic lesion

141 dical hysterectomy or confirm the absence of residual tumor in the cervix after a cone biopsy with ne

142 argins, 71.4% of ABBI and 70.4% of WL bx had residual tumor in the definitive treatment specimen.

143 ot a reliable criterion for the detection of residual tumor in the prostate after cryosurgical ablati

144 Twenty-five percent of the patients with residual tumor in the resected surgical specimen were lo

145 ase-free survival rate for the patients with residual tumor in the surgical specimen were 12.9 months

146 ced spoiled gradient-echo MR imaging depicts residual tumor in women with treated ovarian cancer, wit

147 ectiveness in reducing tumor number, the few residual tumors in mice treated with the combined drugs

148 Increased growth of residual tumors in the proximity of acute surgical wound

149 nsitive in screening for trace quantities of residual tumors in various organs of SCID mice, and it c

150 The ability to detect residual tumor intraoperatively resulted in a radiologic

151 R were clinical N2 or N3 disease, pathologic residual tumor larger than 2 cm, a multifocal pattern of

152 Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual dis

153 ation necrosis with limited recurrent and/or residual tumor (less than 20% of resected tissue) in 16

154 continuation of treatment in the presence of residual tumor mass almost inevitably leads to tumor pro

155 n patients with stage III ovarian cancer and residual tumor masses of 2 cm or less.

156 plication of GCV (10 mg per kg) for 6 d, the residual tumor masses were excised and the animals chall

157 ilization, however, often in the presence of residual tumor masses.

158 eve disease stabilization in the presence of residual tumor masses.

159 inically unsuspected multifocal or extensive residual tumor may lend support for mastectomy rather th

160 The residual tumor measured a mean basal diameter of 10.6 mm

161 In the metastatic setting, residual tumor metabolic activity after the initiation o

162 esent images from human surgery which detect residual tumor not evident with state-of-the-art vFI.

163 Residual tumors obtained from angiostatin- and endostati

164 A postoperative residual tumor of more than 1.5 cm(2) was the strongest

165 ic strategy in selected patients who have no residual tumor on a repeat vigorous resection of the pri

166 tal vein encasement (HR 3.3; P = 0.007), and residual tumor on explant (HR 9.8; P < 0.001).

167 Adult patients with residual tumor on magnetic resonance imaging scan follow

168 dy were 45 years or older and had measurable residual tumor on postoperative MRI scans.

169 Patients with residual tumor on posttreatment biopsy were treated with

170 = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), an

171 patients with complete tumor resection with residual tumor (P =.03).

172 oints; ypN3a to 3b = 3 points; less than 10% residual tumor per tumor bed = 1 point; 10% to 50% resid

173 al tumor per tumor bed = 1 point; 10% to 50% residual tumor per tumor bed = 2 points; and greater tha

174 r tumor bed = 2 points; and greater than 50% residual tumor per tumor bed = 3 points.

175 or distant disease: two stage 2A with gross residual tumor postsurgery, 11 stage 2B with ipsilateral

176 at the primary tumor as defined by extent of residual tumor predicted overall survival (3 years: P0,

177 Sixty-eight women had residual tumor proved at laparotomy and biopsy or at cli

178 The positive margin rates and residual tumor rates are comparable between the ABBI and

179 6), subretinal fluid (P=0.035), thickness of residual tumor scar (P<0.001), and elevation of residual

180 idual tumor scar (P<0.001), and elevation of residual tumor scar (P<0.001).

181 In eyes with residual tumor showing scleral invasion or intraocular i

182 sion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variable

183 ed s.c. FaDu xenograft tumors (i.e., reduced residual tumor size, enhanced apoptotic cell fraction, a

184 nd mammography have all been used to predict residual tumor size, there have been conflicting reports

185 Upon isolation from the tumor, the residual tumor-specific T cells were functionally tolera

186 uniformly in advanced tumors, highlighting a residual tumor-suppressive function conferred by the rem

187 In seven patients, MR imaging depicted residual tumor that was not found at laparotomy but was

188 eliver a continuous lethal radiation dose to residual tumors that are radiosensitized by PARP inhibit

189 hin tumors, thus facilitating the removal of residual tumor tissue during surgical procedures.

190 Complete removal of residual tumor tissue during surgical resection improves

191 he sensitivity of (18)F-FDG PET/CT to detect residual tumor tissue was 92% (95% confidence interval [

192 Histological analysis of residual tumor tissues revealed an almost complete absen

193 correlated with diminished MYC expression in residual tumor tissues.

194 Fourteen operable patients with residual tumor underwent immediate cystectomy.

195 en the patients who had a score negative for residual tumor versus positive for residual tumor.

196 nts with M0 tumors with less than 1.5 cm2 of residual tumor, versus > or = 1.5 cm2 of residual tumor

197 r observation indicated normalization of the residual tumor vessels, which was also implied by low le

198 therapy (EBRT) was necessary in 33 eyes with residual tumor, vitreous seeds, or both.

199 <0.0001, analysis of covariance (ANCOVA)] in residual tumor volume [0.26; 95% confidence interval (95

200 rescence image analysis routines to quantify residual tumor volume and viability.

201 Initial and residual tumor volumes were measured on intraoperative T

202 with all reference assessments and no large residual tumor was 82% +/- 2% at 5 years.

203 The residual tumor was composed only of premalignant epithel

204 ents with positive results, the diagnosis of residual tumor was confirmed at biopsy or by clinical fo

205 Residual tumor was detected after RF thermal ablation in

206 Residual tumor was incorrectly predicted with MR imaging

207 l extension beyond the gross mucosal edge of residual tumor was observed in only 2 patients (1.8%), b

208 No evidence of residual tumor was seen on MR images obtained after the

209 Those with more than 1 cm(3) residual tumor were randomly assigned to receive an addi

210 ppearance in 40% of the animals, wherein the residual tumors were smaller in size with limited or no

211 ients with clinically suspected recurrent or residual tumors were studied with PET using Met as well

212 ) were downregulated in treatment responsive residual tumors, when compared with controls.

213 cantly induced the survivin protein level in residual tumors, whereas addition of PCat-siSurvivin com

214 Forty-four percent of these patients had residual tumor within axillary lymph nodes.